MOMarissa O'CAllaghan

Marissa O'CAllaghan

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Marissa O'CAllaghan has a total of 29 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Reexamining the Role of Pulmonary Lipids in the Pathogenesis of Pulmonary Fibrosis

    by Marissa O’cAllaghan, Elizabeth J. Tarling, James P. Bridges, Elizabeth F. Redente, Adam J. Byrne, Michael P. Keane, Cormac McCarthy

    Pulmonary fibrosis (PF) can be idiopathic or driven by a specific insult, genetic susceptibility, or disease process. Inflammation plays a role in the pathophysiology, the extent of which remains a longstanding topic of debate. More recently, there has been increasing interest in a potential inciting role for aberrant lipid metabolism. Lipids are essential for the structure and function of all cell membranes, but specifically in the lung for surfactant composition, intra- and intercellular lipid mediators, and lipofibroblasts. Clinically, there is evidence of increased lipid deposition in the subpleural space and at a whole-lung tissue level in PF. There is evidence of increased parenchymal lipid deposition and abnormal mediastinal fat shape on chest computed tomography. A protective role for cholesterol-lowering drugs, including statins and ezetimibe, has been described in PF. At a cellular level, fatty acid, phospholipid, and glucose metabolism are disordered, as is the production of lipid mediators. Here we put forward the argument that there is substantive clinical and biological evidence to support a role for aberrant lipid metabolism and lipid mediators in the pathogenesis of PF.


  • Open Access

    Analysis of tissue lipidomics and computed tomography pulmonary fat attenuation volume (CTPFAV) in idiopathic pulmonary fibrosis

    by Marissa O'CAllaghan, John Duignan, Elizabeth J. Tarling, Darragh K. Waters, Megan McStay, Orla O'CArroll, James P. Bridges, Elizabeth F. Redente, Alessandro N. Franciosi, Emmet E. McGrath, et al.

    Background and Objective: There is increasing interest in the role of lipids in processes that modulate lung fibrosis with evidence of lipid deposition in idiopathic pulmonary fibrosis (IPF) histological specimens. The aim of this study was to identify measurable markers of pulmonary lipid that may have utility as IPF biomarkers.Study Design and Methods: IPF and control lung biopsy specimens were analysed using a unbiased lipidomic approach. Pulmonary fat attenuation volume (PFAV) was assessed on chest CT images (CTPFAV) with 3D semi‐automated lung density software. Aerated lung was semi‐automatically segmented and CTPFAV calculated using a Hounsfield‐unit (−40 to −200HU) threshold range expressed as a percentage of total lung volume. CTPFAV was compared to pulmonary function, serum lipids and qualitative CT fibrosis scores.Results: There was a significant increase in total lipid content on histological analysis of IPF lung tissue (23.16 nmol/mg) compared to controls (18.66 mol/mg, p = 0.0317). The median CTPFAV in IPF was higher than controls (1.34% vs. 0.72%, p < 0.001) and CTPFAV correlated significantly with DLCO% predicted (R2 = 0.356, p < 0.0001) and FVC% predicted (R2 = 0.407, p < 0.0001) in patients with IPF. CTPFAV correlated with CT features of fibrosis; higher CTPFAV was associated with >10% reticulation (1.6% vs. 0.94%, p = 0.0017) and >10% honeycombing (1.87% vs. 1.12%, p = 0.0003). CTPFAV showed no correlation with serum lipids.Conclusion: CTPFAV is an easily quantifiable non‐invasive measure of pulmonary lipids. In this pilot study, CTPFAV correlates with pulmonary function and radiological features of IPF and could function as a potential biomarker for IPF disease severity assessment.


  • Diagnostic Utility of Quantitative 3D HRCT Analysis to in Diffuse Cystic Lung Diseases

    by Y. Sekimoto, E. Lynn, J. Morrow, M. O'CAllaghan, A. Jouida, J.D. Dodd, D. Murphy, M.P. Keane, C. Mccarthy